biotech
FDA Approves Exelon For Parkinson Disease Dementia
Filed in archive Drugs, Vaccines and Therapeutics by ruth on June 29, 2006
FDA Approves Exelon For Parkinson Disease Dementia
The US FDA has approved Exelon (rivastigmine tartrate) for the treatment of mild to moderate Parkinson's disease dementia. Exelon, the first drug indicated for this condition, has previously been approved as a therapeutic for Alzheimer's disease.
"It's been recognized for almost a decade that the dementia of patients with Parkinson's disease differs from the dementia of patients with Alzheimer's," said Dr. Steven Galson, Director of FDA's Center for Drug Evaluation and Research, "but until now, there has been no treatment that has been shown to be effective specifically for the dementia associated with Parkinson's Disease. Today's approval of Exelon helps to fill this medical need."

Exelon is a choline esterase inhibitor, which works by increasing the levels on acetylcholine in the brain. It has already secured marketing authorization in Europe and according to a Forbes news report, has already been approved to treat Parkinson's Disease dementia in 14 other countries.



Permalink: FDA Approves Exelon For Parkinson Disease Dementia
Tags: parkinson  alzheimer  biotech  disease  dementia  parkinson+disease  disease+dementia  exelon+parkinson 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/26016
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for FDA Approves Exelon For Parkinson Disease Dementia:

  • Currently 8.00/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 8.00 out of 3 vote(s) cast.
 
Subscribe
Share It
Popular posts from our other blogs:
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!